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Background: The effectiveness of India’s TB control programs depend critically on patients completing appropriate
treatment. Discontinuing treatment prior to completion can leave patients infectious and symptomatic. Developing
strategies to reduce early discontinuation requires characterizing its patterns and their link to symptom persistence.
Methods: The 2011 BEST-TB survey (360 clusters, 11 districts) sampled patients (n = 1007) from Bihar’s public healthcare
system who had initiated treatment >6 months prior to being interviewed, administering questionnaires to patients
about TB treatment duration and symptoms, prior treatment, and sociodemographic characteristics. Multivariate logistic
regression models estimated the risk of treatment discontinuation for these characteristics. Similar models estimated
probabilities of symptom persistence to 25 weeks post-treatment initiation adjusting for the same predictors and
treatment duration. All models included district fixed effects, robust standard errors, and adjustments for the
survey sampling design. Treatment default timing and symptom persistence relied solely on self-report.
Results: 24% of patients discontinued treatment prior to 25 weeks. Higher likelihood of discontinuation occurred
in those who had failed to complete previous TB treatment episodes (aOR: 4.77 [95% CI: 1.98 – 11.53]) and those
seeing multiple providers (3.67 per provider [1.94 – 6.95]). Symptoms persisted in 42% of patients discontinuing
treatment within 5 weeks versus 28% for completing 25 weeks of treatment. Symptom persistence was more
likely for those with prior TB treatment (aOR: 5.05 [1.90 – 13.38]); poorer patients (2.94 [1.51 – 5.72]); and women
(1.79 [1.07 – 2.99]). Predictors for treatment discontinuation prior to 16 weeks were similar.
Conclusions: Premature TB treatment discontinuation and symptom persistence is particularly high among
individuals who have failed to complete treatment for a prior episode. Strategies to identify and promote
treatment completion in this group appear promising. Likewise, effective TB regimens of shortened duration
currently in trials may eventually help to achieve higher treatment completion rates.
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Tuberculosis (TB) represents a major global health bur-
den of particular concern given its growing resistance to
available drugs. India bears the world’s largest TB bur-
den with 3,000,000 cases in 2009 [1]. India’s substantial
efforts to address TB through its public healthcare* Correspondence: jeremygf@stanford.edu
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unless otherwise stated.system have led to declines in TB prevalence and inci-
dence [2]. More recently, India’s public healthcare sys-
tem has also increased its efforts to address the
emergence of multidrug resistant (MDR) TB (MDR
is defined as TB resistant to at least rifampicin and
isoniazid) [1,3-7].
Premature TB treatment discontinuation (i.e., default)
hampers TB control efforts. Early discontinuation im-
plies exposure to TB drugs for durations insufficient to
effect cure. Such exposures may also select for drugLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ger and more toxic than for non-MDR TB [9-14].
Because TB treatment is lengthy, complicated, and poten-
tially toxic, premature treatment discontinuation among a
fraction of patients is almost inevitable, prompting efforts
to reduce the current length of treatment, which exceeds
25 weeks [2]. Development of shorter treatments (e.g., 4-
month regimens containing quinolones) [15,16] could po-
tentially reduce the chance of premature discontinuation
and drug resistance. However, success depends partly on
the timing of discontinuation – if discontinuation happens
frequently in the first month of treatment, shortening regi-
mens to even 2 months would not change cure rates. The
patterns and timing of treatment discontinuation and the
factors predicting discontinuation are not well characterized
in many high TB burden settings.
In India, treatment discontinuation is high as patients
with active TB disease are often poor, socially disadvan-
taged, and under-educated; alcohol use also contributes
to higher discontinuation rates [17-24]. Many patients
first receive ineffective care in the private health sector,
which saps resources and delays their entry into the
public system [25-27]. As their symptoms improve with
effective treatment, continued costs, inconvenience, and
toxicity risks may make remaining on treatment increas-
ingly unappealing. For these reasons, treatment discon-
tinuation likely differs among those who have been
treated previously in the private sector and is likely
linked to the pace at which patients’ symptoms improve.
Understanding differences in patterns of discontinuation
for treatment-experienced and for treatment-naïve pa-
tients is needed because multiple treatment exposures in-
crease the probability of accumulating mutations resistant
to specific medications, raising the risk of MDR TB.
Bihar exemplifies the challenges of India’s TB epidemic
given its historically high levels of poverty and poor
health outcomes [28,29]. Bihar’s population exceeds 100
million people [30] (approximately 10% of India’s total),
its public healthcare system registered 76,484 patients
for TB treatment in 2011 [30], and it likely sees an ap-
preciable proportion of drug resistant TB [30-33].
The present study focuses on patients treated for TB
in Bihar’s public healthcare system. It had two goals: 1)
characterize treatment discontinuation and symptom
persistence despite treatment; and 2) identify character-
istics of TB patients and their healthcare experiences
that predict these outcomes and are potentially amen-




The study analyzes data from the Bihar Evaluation of Social
Franchising and Telemedicine - Tuberculosis (BEST-TB)survey which received Institutional Review Board re-
view and approvals from Duke University and Stanford
University in the U.S. and from Society for the Promotion
of Ethical Clinical Trials – Ethics Review Board (SPECT-
ERB) in India. Research permissions were also granted by
the Governments of India and of the State of Bihar. All
subjects provided written informed consent.Survey, sample and data collection
The 2011 BEST-TB survey, a cross-sectional survey of
TB patients treated in the public healthcare system in
11 districts of Bihar, India, provided data for the
present analysis. The survey occurred in 360 rural clus-
ters (Figure 1) whose sampling was determined as part
of the baseline for a larger evaluation of interventions
for a variety of diseases [34]. To represent patients re-
ceiving care in the public TB healthcare system, we
constructed the sampling frame using TB patient lists
from all Primary Health Centers (PHCs) within the
study clusters as India’s Revised National Tuberculosis
Control Programme (RNTCP) provides standard TB
medications and care free of charge according to the
Directly Observed Treatment Short Course (DOTS)
protocol to an estimated 60% of TB cases [35-39]. For
potential inclusion in the study, enumerators recorded
names and addresses of all TB patients entered on PHC
lists within the past year (July 2010- July 2011) living
within study clusters (i.e., village catchments represent-
ing part of the catchment served by a given PHC).
Combining these names for each cluster generated the
cluster’s sample list. From each cluster’s list, 6 patients
were randomly sampled for study inclusion; all patients
were included from cluster lists with fewer than 6
names. While the planned sample size was 2160, a re-
view of all PHC records indicated that 20 clusters had
no patients treated in the previous year and living
within a study catchment area, and 22% of cluster lists
had ≤6 names. Hence, 1691 patients were selected for
subsequent household survey. There were no additional
exclusion criteria.
Response rates to enumerators visiting and surveying
each patient’s household were high. Just 44 households
(2.6%) were not surveyed because they could not be lo-
cated or no competent respondent was found. Of the
remaining 1647 households, 5 refused (0.3%) and 68 re-
ported that the TB patient had died (4.0%). Additionally,
28 patients provided incomplete data and were excluded.
Household surveys were completed for 1546 patients
(91.4% response rate of households contacted for inclu-
sion). Because the present analyses focus on the treat-
ment experience of patients in the RNTCP public
system which according to DOTS treatment category
should be at least 25 weeks in length, we restricted our
Figure 1 Map of regions surveyed within districts of Bihar (Inset map showing location of Bihar within India). The figure shows the map
of Bihar and its districts. Gray areas represent the survey regions containing the 360 study clusters. Hashed areas represent survey regions with no
TB patients eligible for study inclusion. The inset map of India shows the state of Bihar (Black) along with all other Indian states.
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prior to the interview (1007 patients).
Based on each TB patient’s responses to the question-
naire, we reconstructed a timeline of his or her illness
and treatment relying solely on patient self-report. Be-
cause of the high variability of data recorded in the treat-
ment records at the PHCs in our prior piloting of the
survey, we did not use these records for our analysis.
Instead, we relied solely on patients reporting their de-
tailed experiences of common TB symptoms: persistent
cough (≥3 weeks), coughing blood, fever, weight loss, night
sweats, chronic fatigue, and loss of appetite [40,41]. We
recorded their reported number of days since the onset of
each symptom and the number of days each persisted. We
recorded the number of days each patient waited to seek
care, before a diagnosis was received, and before begin-
ning treatment. Finally, we recorded the number of days
each patient reported remaining on treatment in the pub-
lic system. We refer to the patient’s most recent episode of
TB as the current episode, regardless of whether the pa-
tient remained ill at the time of survey. Patients also pro-
vided information about treatment for TB prior to the
current episode, demographic characteristics, household
composition and household assets.Outcomes
Main outcomes were treatment discontinuation prior to
25 weeks (hereafter simply “treatment discontinuation”)
and symptom persistence. Given policy interest in
shorter treatment regimens, we repeated our analysis
for treatment discontinuation prior to 16 weeks. Given
policy interest in shorter treatment regimens and
heterogeneity in current treatment regimens, we re-
peated our analysis for treatment discontinuation prior
to 16 weeks for the entire sample and prior to 32 weeks
for those with prior TB treatment episodes. Symptom
persistence was defined as having ≥1 TB symptom
25 weeks after treatment initiation. We also explored an
alternate model using the number of TB symptoms
present at 25 weeks.
Predictors
Main predictors of treatment discontinuation and symp-
tom persistence were reporting treatment for a prior epi-
sode of TB and completion of prior TB treatment. It is
unclear whether those with prior TB treatment are more
or less likely to complete treatment for their current epi-
sode. If patients are already familiar with treatment,
those choosing to repeat treatment may remain in care
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have undergone prior TB treatment may experience
treatment fatigue and discontinue earlier. Failure to
complete the prior TB treatment is hypothesized to pre-
dict early discontinuation from the current treatment
episode. Because repeated treatment can select for MDR
particularly if treatment is not completed and MDR is
more difficult to cure [32,42], we also hypothesize that
both prior TB treatment and failing to complete prior
treatment predict symptom persistence at the end of the
current episode of treatment, while noting that there are
other reasons for symptoms to persist (residual lesions
even after cure; other respiratory ailments) which we
cannot distinguish.
TB illness, treatment, and costs
A patient’s total number of symptoms at the time of
seeking care proxied for illness severity at baseline. We
controlled for treatment delays in two ways [43-51].
First, we used the number of weeks between symptom
onset and treatment initiation. Second, we used the
number of treatment providers seen for the current epi-
sode. Additionally, although treatment for TB through
RNTCP should be free to the patient, we included indi-
cators for whether the patient reported paying for ser-
vice or medication fees, for travel to the site of care, or
both [37,52]. We hypothesized that more severely ill pa-
tients remain in care longer, but are also more likely to
have symptoms persist. The relationship of treatment
discontinuation to both delays in seeking treatment and
for having seen additional providers prior to treatment
in the public system was unclear. If illness severity
worsens with longer delays, patients may remain in care
longer. However, treatment delays may indicate unob-
served characteristics that imply higher discontinuation
rates. We hypothesize that both treatment delays and
seeing more providers are associated with greater symp-
tom persistence. We hypothesize that paying for service
and medications fees and travel costs are associated with
higher treatment default and consequently with greater
symptom persistence.
Patient and household characteristics
We included patient sex, religion (Hindu vs. non-
Hindu), social group (scheduled caste, scheduled tribe,
or other backwards class vs. other castes), age (years),
and education (0 if illiterate and number of years of edu-
cation among the literate). We hypothesize that men,
Hindus, those with higher education and those belong-
ing to “other castes” remain in care longer and are less
likely to have symptom persistence [37,53-55]. House-
hold assets proxied for wealth based on a wealth index
constructed using a standard principle components
analysis of assets [56] and then grouped householdsinto relative wealth tertiles, acknowledging that most
TB households are not wealthy compared to India’s
general population [57]. We accounted for household
composition in two ways: the number of people
residing in the home and number of children below
age 5 in the home. We hypothesized that patients from
the poorest households are more likely to discontinue
treatment prior to 25 weeks [37,53-55,58]. If larger house-
holds have more resources to compensate for lost work
and time devoted to TB treatment, then patients from lar-
ger households will remain in care longer. However, the
demands associated with children in the household imply
higher opportunity costs of continued treatment. We
therefore expect that number of children is positively cor-
related with treatment discontinuation. The combined ef-
fects of household composition on symptom persistence
were unclear.
Statistical analysis
We predicted the likelihood of ending treatment before
25 weeks using a multivariate logistic regression model.
We estimated the model using all 1007 patients control-
ling for prior TB treatment and treatment completion,
repeating the analysis separately for 196 patients with
prior TB treatment and for 811 with no prior treatment
to examine differential effects of other predictors within
these subgroups. The Supporting Information also re-
ports a linear probability model of treatment discontinu-
ation prior to 25 weeks and both logistic regression and
linear probability models of treatment discontinuation
prior to 16 weeks of treatment for the entire sample and
prior to 32 weeks for those with prior TB treatment epi-
sodes. We likewise assessed determinants of symptom
persistence 25 weeks after treatment initiation using a
multivariate logistic model. The Supporting Information
also reports a negative binomial model for the number
of symptoms persisting 25 weeks post treatment initi-
ation. For symptom persistence, we included the same
predictors as for default along with duration in treat-
ment covariates. We explored multiple definitions of
duration of treatment including an indicator for com-
pleting ≥180 days of treatment; number of weeks of
completed treatment; and indicators for completing 0-8
weeks, 9-16 weeks, and >16 weeks.
For all analyses, the multivariate models did not em-
ploy variable selection techniques but instead included
all predictors for which there was a theory-predicted re-
lationship to the outcome. Likewise, for all analyses, we
included district-level fixed effects to control for unob-
served characteristics of healthcare systems, geographic
areas, and patient populations within each district. We
also adjusted for survey design using inverse probability
sampling weights and calculated robust standard errors
clustered by sampling unit [59].
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Table 1 reports descriptive statistics for the sample of
1007 TB patients receiving treatment in the public health-
care system in Bihar who initiated treatment >180 days
prior to their household interview. Their characteristics
were generally consistent with those reported for other
Indian TB populations [35-39].Figure 2 Cumulative risk of treatment default stratified by prior
TB treatment and prior treatment completion. The figure shows
the proportion of TB patients who have ended treatment during the
first 25 weeks of treatment. In addition to showing the overall rate of
treatment default (solid line), separate curves are shown for patients
with no prior TB treatment episodes, patients with prior TB episodes
where they completed prior treatment, and patients with prior TB
episodes where they did not complete treatment.Treatment discontinuation
Individuals who did not complete treatment for prior
episodes of TB have differentially higher probabilities of
discontinuing treatment prior to 25 weeks in their
current TB treatment episode compared to those with
no prior episodes and those who completed treatment
for their prior episodes (Figure 2). More than 69% [95%
CI 50-89%] of the 39 patients who reported that they
had not completed their previous TB treatment also
failed to complete at least 25 weeks of their current
treatment (median time to default 17 weeks) compared
to 28% [95% CI: 16-40%] of the 157 patients who re-
ported completing their previous treatment and 21%
[95% CI: 17-26%] of the 811 patients treated for the firstTable 1 Description of TB patients







N 1007 811 157 39
Percent of all patients 80% 16% 4%
Patient characteristics
Male % 67.4% 68.3% 66.3% 54.9%
Mean age Yrs 37.4 37.4 37.2 36.6
Literate % 36.9% 39.1% 27.3% 31.8%
Education: mean amount of schooling (If Literate) Yrs 7.15 7.20 6.66 7.79
Scheduled Caste, scheduled Tribe, other backward class % 91.5% 91.3% 92.3% 90.3%
Hindu % 88.9% 89.3% 88.2% 84.2%
Household characteristics
Household size # 6.59 6.43 7.36 6.37
Number of children under 5 # 1.64 1.59 1.87 1.70
Treatment and illness
Total weeks from symptom onset to treatment initiation Wks 6.05 6.01 6.33 5.63
Number of providers visited # 1.07 1.04 1.18 1.25
Any treatment or medication fees % 63.9% 59.2% 85.3% 68.2%
Any travel costs % 79.4% 79.5% 78.4% 82.0%
Mean total cost of treatment among those paying any
costs/fees
Rupees 318 296 385 456
2 or fewer symptoms at treatment initiation % 46.7% 50.5% 23.1% 69.9%
3-4 symptoms at treatment initiation % 18.7% 18.3% 21.6% 14.1%
≥5 symptoms at treatment initiation % 34.6% 31.1% 55.4% 16.0%
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respectively).
Individuals who had prior TB episodes but did not
complete treatment have higher probability of discon-
tinuing their current treatment episodes after adjusting
for multiple factors (adjusted Odds Ratio (aOR): 4.77
[95% CI: 1.98 – 11.53]) (Table 2). Discontinuation prob-
abilities of those who completed prior TB treatment are
similar to those without prior treatment (approximately
1.05 after combining the aOR for prior TB with the
interaction aOR for completing prior treatment: 0.22
[95% CI: 0.08 – 0.59]). Seeing more treatment providers
for the current episode of TB predicts higher probabil-
ities of treatment discontinuation (aOR: 3.67 per pro-
vider seen [95% CI: 1.94 – 6.95]). When one considers
the effects of paying for treatment costs, travel costs,
and the amount paid, paying anything predicts higher





Prior TB treatment episode 6.15* (2.60 - 14
Prior TB & completed prior treatment 0.23* (0.09 - 0
Current illness treatment and illness characteristics
Total weeks from symptom onset to treatment
initiation
1.00 (0.95 - 1
Number of Providers visited 4.68* (2.64 - 8
Treatment or medication fees 6.83* (2.18 - 21
Travel costs 2.70* (1.07 - 6
Treatment, medication and travel costs 0.21* (0.06 - 0
2 or fewer symptoms at treatment initiation** 1.18 (0.75 - 1
3-4 symptoms at treatment initiation** 1.38 (0.74 - 2
Patient and household characteristics
Male 1.29 (0.85 - 1
Age 0.96 (0.91 - 1
Age squared 1.00 (1.00 - 1
Education 1.01 (0.96 - 1
Hindu 0.83 (0.51 - 1
Scheduled Caste, Tribe, other backwards class 0.87 (0.53 - 1
Number of Kids 0.95 (0.82 - 1
Household size 0.97 (0.88 - 1
Poor 1.09 (0.68 - 1
Middle income 0.70 (0.36 - 1
Observations 1007
*p < 0.05.
**Comparator group is ≥5 Symptoms at Treatment Initiation.able to pay more and choose to do so are less likely to
discontinue treatment.
Predictors of treatment discontinuation are distinct
when the analysis is repeated separately for those with and
without prior TB treatment. Significant predictors of
higher probability of treatment discontinuation among
those treated for TB previously are having not completed
the prior episode of TB treatment along with personal
characteristics including having fewer TB symptoms at
the time of treatment initiation, younger age, less educa-
tion, and being non-Hindu. In contrast, for those who had
not been treated previously, significant predictors of
greater probability of treatment discontinuation were not
individual characteristics including number of symptoms
as a marker for illness severity but rather care seeking
pathways like the number of providers seen for the
current episode of TB treatment and payment for
treatment and related costs. The direction of thesefter treatment initiation: logistic regression results
sion Multivariate regressions




I) OR (95% CI) OR (95% CI) OR (95% CI)
.53) 4.77* (1.98 - 11.53)
.60) 0.22* (0.08 - 0.59) 0.15* (0.03 - 0.73)
.05) 1.02 (0.97 - 1.07) 1.04 (0.90 - 1.20) 1.02 (0.97 - 1.08)
.27) 3.67* (1.94 - 6.95) 3.08 (0.46 - 20.45) 5.62* (2.32 - 13.66)
.41) 4.60* (1.38 - 15.40) 1.13 (0.08 - 16.48) 6.32* (1.43 - 28.00)
.82) 2.55* (1.03 - 6.33) 1.43 (0.13 - 16.08) 4.39* (1.36 - 14.13)
.69) 0.34 (0.10 - 1.18) 1.04 (0.05 - 21.04) 0.19 (0.03 - 1.06)
.85) 1.62 (0.96 - 2.73) 4.20* (1.26 - 13.92) 1.29 (0.76 - 2.21)
.56) 1.54 (0.83 - 2.86) 2.55 (0.66 - 9.95) 1.16 (0.65 - 2.09)
.95) 1.32 (0.82 - 2.14) 1.02 (0.39 - 2.69) 1.34 (0.81 - 2.22)
.00) 0.96 (0.91 - 1.01) 0.84 (0.70 - 1.01) 0.98 (0.93 - 1.03)
.00) 1.00 (1.00 - 1.00) 1.00* (1.00 - 1.00) 1.00 (1.00 - 1.00)
.06) 0.99 (0.93 - 1.06) 0.75* (0.58 - 0.98) 1.01 (0.95 - 1.07)
.35) 0.81 (0.47 - 1.40) 0.25* (0.08 - 0.78) 0.97 (0.51 - 1.84)
.44) 0.84 (0.47 - 1.50) 0.36 (0.08 - 1.71) 1.02 (0.51 - 2.02)
.09) 1.02 (0.86 - 1.21) 0.80 (0.53 - 1.20) 1.08 (0.89 - 1.31)
.06) 0.96 (0.86 - 1.07) 1.35 (0.97 - 1.88) 0.92 (0.81 - 1.04)
.74) 0.97 (0.56 - 1.66) 0.76 (0.14 - 4.11) 1.27 (0.73 - 2.19)
.36) 0.86 (0.48 - 1.54) 0.99 (0.30 - 3.20) 0.95 (0.56 - 1.61)
1007 196 811
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are repeated using a linear probability model though at
times significance attenuates (see Additional file 1).
The predictors of treatment discontinuation within
4 months of starting treatment are consistent with the re-
sults of the main analysis – having had prior TB treatment
that was not completed (aOR: 4.63 [95% CI: 1.88 –
11.42]), and seeing more providers (aOR per provider:
5.60 [95% CI: 2.18 – 14.37]) (see Additional files 2 and 3).
Symptom persistence
Symptoms persisted 25 weeks after treatment initi-
ation for 28% of patients despite remaining in treat-
ment for at least 25 weeks (Figure 3). Among patients
discontinuing treatment early, symptoms persisted in 42%
of patients completing ≤5 weeks, 33% of patients complet-
ing ≤10 weeks, and 30% of patients completing ≤18 weeks.
Symptoms most likely to persist despite 25 weeks of treat-
ment include fatigue (18% of patients), appetite loss (16%),
night sweats (15%), weight loss (14%) and coughing (11%)
(Figure 3). Persistence of symptoms followed different tra-
jectories for those with and without prior TB treatment
with symptoms more likely to persist for those with prior
TB treatment (Figure 3).
TB symptom persistence 25 weeks post treatment ini-
tiation is more likely for those with prior TB treatment
(aOR: 5.05 [95% CI: 1.90 – 13.38]), poorer patients (aOR
for lowest wealth tertile among TB households: 2.94
[95% CI: 1.51 – 5.72]), and women (aOR of men com-
pared to women: 0.56 [95% CI: 0.33 – 0.93]) (Table 3).
For those with prior TB, the main predictors of symp-
tom persistence are the number of treatment providers
seen (aOR per provider seen: 3.76 [95% CI: 1.00 –
14.11]) (Table 3). For those with no prior TB, the main
predictors of symptom persistence are not actually pay-
ing for treatments, medications and travel which is likely
a marker of poverty in terms of the inability to pay, and
poverty as explicitly measured by being in the lowest
wealth tertile among TB households (aOR: 2.91 [95% CI:
1.50 – 5.68]) (Table 3). Notably, number of symptoms at
treatment initiation did not predict symptom persistence.
Results for predictors of symptom persistence remain
largely consistent when the number of symptoms
present 25 weeks after treatment initiation is used as the
outcome, when different specifications for time in treat-
ment are used as predictors in both linear probability
models and logistic regression models, and when we es-
timate a model of symptom persistence 16 weeks after
treatment initiation (see Additional files 4,5 and 6).
Discussion
24% of surveyed TB patients reported failing to complete
at least 25 weeks of treatment in Bihar’s public healthcare
system. The rate of premature treatment discontinuationwas nearly 59% for patients who had previously started
but not finished TB treatment. High discontinuation rates
are concerning given that a proportion of these patients
that undergo inappropriately short treatment may remain
infectious and because ineffective exposures to TB medi-
cations may select for drug resistant mutations. For 28%
of patients, symptoms persist after 25 weeks of treatment;
symptom persistence is even more common for those dis-
continuing treatment and for patients previously treated
for TB, suggesting a lack of cure in some patients.
Our study contributes to the prior literature [17-24]
and extends knowledge by connecting premature treat-
ment discontinuation and symptom persistence. Main
predictors of treatment discontinuation are consistent
with prior studies as are those for symptom persistence.
The link between treatment discontinuation and symp-
tom persistence especially in patients receiving repeated
TB treatment over multiple illness episodes is important
because it illustrates a subgroup of patients who may
benefit from further supportive interventions and who
are important candidates for further TB and MDR TB
control efforts.
TB treatment in the private healthcare sector plays a
role in our analysis as a predictor of treatment discon-
tinuation and symptom persistence but is also addition-
ally important in its own right. Limited data from the
private healthcare sector and from the studies evaluating
public-private partnerships for TB treatment [60-62]
suggest that, in these settings, treatment duration is
often too short, provider switching too frequent, and de-
lays in care too long. We know of no data examining
symptom persistence after treatment in these settings.
Given that approximately 40% of patients are treated in
these settings even if they ultimately receive care in the
public healthcare sector, studies similar to ours evaluat-
ing outcomes in the private healthcare sector in a repre-
sentative patient population could provide substantial
new insights to enable the improvement of TB care.
Our findings suggest areas for policy design. Strategies
that increase cure rates and link private providers to the
public system so patients receive prompt, effective treat-
ment [47,60,63] could potentially reduce TB treatment
discontinuation and symptom persistence. This is sup-
ported by our findings that in addition to higher treatment
discontinuation rates and greater symptom persistence in
those who have been treated for prior TB episodes, treat-
ment discontinuation rates and symptom persistence for
the current episode are higher among individuals who
sought care with private providers before being treated in
the public system. Likewise, programs that reach margin-
alized groups are needed given symptom persistence is
higher among women and the poor.
Our findings regarding the timing of treatment discon-
tinuation (Figure 2) also support the potential benefits of
Figure 3 Proportion of TB patients with symptoms persisting by time since treatment initiation. The figure shows the proportion of
patients with any symptoms and with specific symptoms a given number of weeks after treatment initiation for all patients and stratified by
patients with and without prior TB episodes.
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thus reduce required treatment duration [15,16]. Rates
at which patients discontinue treatment are relatively
constant over 25 weeks and do not appear to beespecially high during the first few months. Further, pre-
dictors of treatment discontinuation before 16 weeks fol-
low the same pattern as those for 25 weeks (Additional
files 2 and 3). These findings suggest that reducing








OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Prior TB status
Prior TB treatment episode 4.59* (2.17 - 9.70) 5.05* (1.90 - 13.38)
Prior TB & completed prior treatment 1.63 (0.58 - 4.62) 2.40 (0.78 - 7.37) 0.81 (0.26 - 2.48)
Current illness treatment and illness characteristics
Total weeks from symptom onset to treatment initiation 1.01 (0.97 - 1.05) 0.96 (0.91 - 1.01) 0.95 (0.86 - 1.05) 0.96 (0.89 - 1.02)
Number of providers visited 2.73* (1.42 - 5.25) 2.06 (0.93 - 4.56) 3.76* (1.00 - 14.11) 1.10 (0.25 - 4.86)
Treatment or medication fees 2.79* (1.16 - 6.71) 1.17 (0.42 - 3.25) 1.30 (0.12 - 14.46) 1.59 (0.43 - 5.92)
Travel costs 2.16* (1.10 - 4.27) 1.89 (0.91 - 3.92) 0.73 (0.06 - 8.66) 1.74 (0.81 - 3.70)
Treatment, medication and travel costs 0.13* (0.05 - 0.33) 0.16* (0.06 - 0.46) 1.30 (0.08 - 22.00) 0.10* (0.03 - 0.39)
Remained in care 0-8 weeks 1.59 (0.73 - 3.43) 0.50 (0.19 - 1.35) 0.35 (0.08 - 1.55) 0.70 (0.17 - 2.89)
Remained in care 9-16 weeks 0.90 (0.31 - 2.61) 0.90 (0.29 - 2.76) 0.29 (0.07 - 1.17) 2.12 (0.75 - 6.02)
2 or Fewer symptoms at treatment initiation** 0.95 (0.57 - 1.58) 1.10 (0.64 - 1.89) 0.89 (0.28 - 2.84) 1.93 (0.96 - 3.88)
3-4 symptoms at treatment initiation** 0.57 (0.28 - 1.16) 0.50 (0.18 - 1.43) 0.42 (0.12 - 1.45) 1.11 (0.37 - 3.35)
Patient and household characteristics
Male 0.66* (0.45 - 0.96) 0.56* (0.33 - 0.93) 0.41 (0.15 - 1.12) 0.76 (0.45 - 1.30)
Age 0.97 (0.92 - 1.01) 0.97 (0.91 - 1.03) 0.97 (0.88 - 1.07) 0.96 (0.90 - 1.03)
Age squared 1.00* (1.00 - 1.00) 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
Education 0.95 (0.91 - 1.00) 1.02 (0.95 - 1.09) 0.99 (0.87 - 1.13) 0.99 (0.92 - 1.06)
Hindu 0.65 (0.41 - 1.03) 0.54 (0.27 - 1.08) 0.61 (0.10 - 3.94) 0.49 (0.22 - 1.08)
Scheduled Caste, Tribe, other backwards class 0.85 (0.52 - 1.38) 0.90 (0.51 - 1.59) 0.71 (0.09 - 5.56) 0.92 (0.46 - 1.86)
Number of Kids 1.02 (0.88 - 1.19) 1.03 (0.84 - 1.28) 0.78 (0.54 - 1.12) 1.14 (0.88 - 1.49)
Household size 1.06 (0.96 - 1.17) 0.99 (0.87 - 1.13) 1.18 (0.89 - 1.57) 0.90 (0.77 - 1.06)
Poor 2.37* (1.44 - 3.91) 2.94* (1.51 - 5.72) 1.89 (0.66 - 5.38) 2.91* (1.49 - 5.68)
Middle income 0.86 (0.45 - 1.63) 1.02 (0.52 - 2.00) 0.81 (0.24 - 2.73) 0.84 (0.48 - 1.47)
Observations 1007 1007 196 811
*p < 0.05.
**Comparator group is ≥5 Symptoms at Treatment Initiation.
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http://www.biomedcentral.com/1471-2458/14/418treatment duration from 25 weeks to 16 weeks could
yield an absolute percentage point increase in treatment
completion of almost 10%.
While one might expect highest default rates early on
in treatment, at least for those individuals with prior TB
treatment, the rate of default increases 45-90 days after
treatment initiation (see Additional file 7). While one
might have anticipated higher rates of discontinuation
during the difficult period of injectable use, our finding
could potentially be explained by patients believing that
“real, necessary treatment” was over because they simply
felt better or because they believed that injections con-
stituted effective treatment and that phase of their treat-
ment was over [64].
Our study has several limitations. Patients sampled are
from Bihar only. While other states differ in terms of TBcare and outcomes [2,30], Bihar’s population of 100 mil-
lion represent roughly 10% of India’s total and is larger
than most high burden countries. Patients are only sam-
pled from the public healthcare sector, and, therefore,
the study cannot comment on individuals who receive
care only in the private sector, though other research
shows high levels of provider switching in the private
sector [39,46] and low levels of effective medication use
[25-27]. Likewise, information on alcohol consumption
in the BEST survey was limited and could not be in-
cluded in the present analysis, though other prior studies
have found that alcoholism is linked to TB treatment de-
fault [65,66].
An important study limitation is the reliance on self-
report of default and default timing as well as TB status
and symptoms without external validation. Our findings
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http://www.biomedcentral.com/1471-2458/14/418of default rates differ from those reported for compar-
able areas of Bihar and are generally substantially lower,
though we note the appreciable heterogeneity across dis-
tricts on numerous measures of program performance
with some districts performing at 50% of other districts
(Additional files 8,9,10 and 11) [67-72]. The difference
in default rates could result from under-reporting of de-
fault in official government reports, over-reporting of
default on the part of patients, or a combination of the
two. Our study is unable to distinguish between these
possibilities, though even if levels of default differ or are
not perfectly representative of all of Bihar or other parts
of India, differentially higher default rates among indi-
viduals who have had multiple exposures to TB drugs,
as is also seen in official reports (Additional files 8,9,10
and 11), and ongoing symptoms are clearly of concern.
The study does not include clinical measures (i.e., spu-
tum smears or drug sensitivity testing) or other adminis-
trative records that were found to be frequently
incomplete in the study areas. For this reason, specific
medications and dosing, laboratory tests and results are
absent from the analysis. Furthermore, self-report is sub-
ject to potential recall bias. We therefore select out-
comes and interpret results conservatively. We consider
the persistence of symptoms suggestive of failure to
achieve cure and chronic disease at least in some pa-
tients but note that although the elimination of symp-
toms is of high value to patients, absence of symptoms
does not prove cure, since it is also consistent with sup-
pression to latent infection. Furthermore, while we adjust
for symptom presence at baseline, symptom persistence
could imply the presence of other illnesses or the lasting
effects of TB even post-cure. Likewise, we focus on treat-
ment default which is linked to lower TB cure rates in the
context of the well-documented selection for resistance
that occurs with exposure to TB medication for insuffi-
cient duration but purposively avoid definitive conclusions
about multidrug resistance status, which we cannot ascer-
tain without laboratory measures.
DOTS regimens employ particular combinations med-
ications for durations that are differentiated for reasons
including past TB treatment [73,74]. While our data did
not permit a clear delineation of which respondent was
on 6 months of Category I DOTS treatment versus
8 months of Category II DOTS treatment, in an analysis
confined to individuals previously treated for TB who
should be in Category II treatment (see Additional files
12 and 7), we found that treatment discontinuation rates
appeared higher among patients who had not completed
their prior episodes of TB treatment relative to those
who had 45-90 days after the start of treatment and that
predictors of treatment discontinuation prior to 8 months
were similar to those for prior to 6 months, though power
to achieve statistical significance was limited. Thesefindings may be explained in part by the fact that Category
II includes an additional, injectable drug (Streptomycin)
and a longer intensive phase which might be expected to
result in a higher default rate given additional toxicities/
side effects (including pain of injections) and
inconvenience.
Given that it is commonly believed that at least 6 months
of treatment is required to ensure cure in >95% of cases
and that the 6-month benchmark is commonly used to as-
sess TB treatment programs, we assessed discontinuation
using a logistic regression with discontinuation coded
as 1 regardless of whether an individual had completed
1 or 5 months of treatment prior to discontinuing. Al-
ternative survival analyses like those using Cox propor-
tional hazards models can be used to analyze outcomes
and may well provide important additional information
and power, though mapping from the hazard rate ratios
they produce to questions about the likelihood of com-
pleting at least 6 months of treatment is substantially
less straightforward.
The links between treatment discontinuation and symp-
tom persistence and the mediation of this effect by prior
episodes of TB treatment are a complex area of study.
Methods like time series analyses that assess evidence of
Granger causality along with marginal structural modeling
techniques may be useful in further elucidating the nu-
ances of these relationships in future work.Conclusions
Premature TB treatment discontinuation remains a sub-
stantial problem in 11 districts in Bihar especially among
individuals who repeatedly seek TB care. Over 25% of
patients have persistent symptoms 25 weeks after treat-
ment initiation; and symptom persistence is more likely
for those defaulting early, previously treated and the
poor. These are concerning findings given bacteriologic
evidence from other studies on the greater likelihood of
continued infectiousness among individuals who termin-
ate treatment early and the role of treatment discontinu-
ation in the selection of multidrug resistance. Approaches
that reduce treatment discontinuation and symptom per-
sistence should be considered as part of efforts to bolster
TB control in settings like Bihar.Additional files
Additional file 1: Table S1. Linear Probability Model of Treatment
Discontinuation.
Additional file 2: Table S2. Likelihood of Treatment Discontinuation
<16 Weeks after Treatment Initiation: Logistic Regression Results.
Additional file 3: Table S3. Linear Probability Model of Treatment
Discontinuation <16 Weeks after Treatment Initiation.
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